



## Cardiac Computed Tomography 2.0

### Adding Physiology to Anatomy

Koen Nieman, MD, PhD,<sup>a</sup> Leslee J. Shaw, PhD,<sup>b</sup>  
Y. Chandrashekhar, MD<sup>c</sup>



Computed tomography angiography (CTA) is now an established diagnostic option for patients with chest pain. It is a safe alternative to functional testing, provides diagnostic certainty (1), is a good gatekeeper for downstream invasive angiography, and increases the diagnostic yield when invasive angiography is eventually needed (2). CTA-driven care is associated with more relief of angina (3,4) and generates optimal medical therapy (5) associated with reduced death and myocardial infarction (6). However, CT angiography can lead to more cardiac catheterizations as well as more coronary revascularization (2). CTA shows good sensitivity, but also suffers from suboptimal specificity; thus, one cannot be sure, lacking other functional test results, that more revascularization procedures are necessary or beneficial compared to operating on lesions with demonstrated ischemia.

What to do after CT identifies a significant stenosis remains unclear. Three randomized controlled trials from Europe reported in this issue of *iJACC* clarify the use of value-added cardiac CT applications such as CT-derived fractional flow reserve (FFR) and CT

perfusion (CTP) to assess the hemodynamic severity of angiographic lesions.

CT-FFR is an effective test in trials (7) as well as in the real-world milieu (8,9), and knowledge about CT-FFR changes practice (10,11) and outcomes (12). Newer technology may ease its use (13,14), and some guidelines are already positive for its role (15). However, its superiority over other noninvasive functional tests is still not clear, which makes the study by Sand et al. (16) very timely. These investigators compared CT-FFR and myocardial perfusion imaging by single-photon emission computed tomography (SPECT) performed in the same patient and using invasive FFR as the gold standard. By studying CTA of stenoses of intermediate severity, the authors focused on the lesions where functional information had most to contribute but were most vulnerable when it came to classifying hemodynamic significance (17). CT-FFR was the most sensitive technique (91%), identifying nearly all functionally significant lesions, which was offset by a specificity of only 55%. Although previous studies have also showed some degree of underestimation by CT-FFR, in this study, the specificity was lower by comparison (7,18). SPECT showed contrasting performance, not great but still better specificity (86%) than CT-FFR, offset by a sobering sensitivity of 41%. Once again, it shows that there is no perfect test and that one should harness the strengths and limitations of each technique to answer specific clinical questions.

Cardiac CT is a good test for rapid discharge of patients with acute chest pain presenting to the

From the <sup>a</sup>Cardiovascular Institute, Stanford University School of Medicine, Stanford, California; <sup>b</sup>Weill Cornell Medical College, New York, New York; and the <sup>c</sup>Division of Cardiology, University of Minnesota and VA Medical Center, Minneapolis, Minnesota. Dr. Nieman is supported by unrestricted institutional research grants from Siemens Healthineers, Bayer Healthcare, GE Healthcare, and Heartflow. Drs. Shaw and Chandrashekhar have reported that they have no relationships relevant to the contents of this paper to disclose.

emergency department. Once patients have been discharged, guidelines call for stress testing in the early follow-up period to assess for flow-limiting coronary artery disease. This allows for the use of advanced CT applications, where a test with high specificity (CTA+CTP) may improve decision making over a test with just high sensitivity (e.g., CTA). CTP can improve clinical decision making (11) and may even be better (19). In the theme of harnessing the advantages of different testing strategies, the CATCH-2 trial (20) randomized patients to undergo a standard CT angiogram or a CTA combined with myocardial perfusion imaging (CTA+CTP). Although the primary endpoint (revascularization in patients sent for invasive angiograms) was, interestingly, high in both groups and, surprisingly, no different, the total invasive angiograms and total revascularizations were significantly less in the CTA+CTP group. Adding physiology to anatomy may show clearer benefit in a more robustly powered future trial.

The value of adding physiology (CTP) to anatomic imaging was also part of the randomized, multicenter CRESCENT-2 trial (21), but now in the context of stable chest pain. Compared to standard care by stress testing, a tiered CT protocol (calcium scan followed by a CT angiogram, if calcium was present, and a dynamic myocardial perfusion scan in case stenotic disease was observed) provided a faster diagnosis, required fewer additional tests, and decreased the number of invasive angiograms that did not require intervention. Although the catheterization rate was similar for both groups, 88% of patients in the CT arm showed coronary artery disease with an indication for revascularization, compared to only 50% in the

functional testing group. By leveraging the high negative predictive value of calcium imaging and CT angiography to rule out coronary disease, while reserving perfusion imaging to guide catheterization and revascularization decisions, median cumulative radiation dose was 3.1 mSv. Adding value-added CT techniques, especially in a tiered manner, may thus improve efficient decision making.

Both the CATCH-2 and CRESCENT-2 trials underline the value of functional testing once coronary stenoses are found on CT angiography. Contrary to some prior trials, these studies showed cardiac CT does not need to be associated with more invasive procedures and that both approaches can lead to more meaningful revascularization decisions based on a comprehensive evaluation of anatomy and function. *iJACC* is an ardent supporter of evidence-based studies, and imaging has been an area with a noticeable deficiency in randomized controlled trials. It is gratifying that we could bring you 3 such trials that will impact future thinking in evaluating patients with intermediate degrees of coronary artery stenosis. This issue of *iJACC* also offers a tantalizing prospect of tiered strategies for optimum clinical utility and may help convince the clinical community to think about an upgrade to cardiac CT version 2.0.

---

**ADDRESS FOR CORRESPONDENCE:** Dr. Y. Chandrasekhar, Division of Cardiology, University of Minnesota/VA Medical Center, Cardiology (111C), 1 Veterans Drive, Minneapolis, Minnesota 55417. E-mail: shekh003@umn.edu.

---

## REFERENCES

1. SCOT-HEART Investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. *Lancet* 2015;385:2383-91.
2. Douglas PS, Hoffmann U, Patel MR, et al., for the PROMISE Investigators. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med* 2015;372:1291-300.
3. Lubbers M, Dedic A, Coenen A, et al. Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial. *Eur Heart J* 2016;37:1232-43.
4. McKavanagh P, Lusk L, Ball PA, et al. A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. *Eur Heart J Cardiovasc Imaging* 2015;16:441-8.
5. Emami H, Takx RAP, Mayrhofer T, et al. Non-obstructive coronary artery disease by coronary CT angiography improves risk stratification and allocation of statin therapy. *J Am Coll Cardiol Img* 2017;10:1031-8.
6. SCOT-HEART Investigators. Coronary CT angiography and 5-year risk of myocardial infarction. *N Engl J Med* 2018;379:924-33.
7. Nørgaard BL, Leipsic J, Gaur S, et al., for the NXT Trial Study Group. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). *J Am Coll Cardiol* 2014;63:1145-55.
8. Nørgaard BL, Hjort J, Gaur S, et al. Clinical use of coronary CTA-derived FFR for decision making in stable CAD. *J Am Coll Cardiol Img* 2017;10:541-50.
9. Douglas PS, De Bruyne B, Pontone G, et al. 1-year outcomes of FFRct-guided care in patients with suspected coronary disease: the PLATFORM study. *J Am Coll Cardiol* 2016;68:435-45.
10. Curzen NP, Nolan J, Zaman AG, et al. Does the routine availability of CT-derived FFR influence management of patients with stable chest pain compared to CT angiography alone? The FFRCT RIPCARD study. *J Am Coll Cardiol* 2016;9:1188-94.
11. Coenen A, Rossi A, Lubbers MM, et al. Integrating CT myocardial perfusion and CT-FFR in the work-up of coronary artery disease. *J Am Coll Cardiol Img* 2017;10:760-70.
12. Nørgaard BL, Terkelsen CJ, Mathiasen ON, et al. Clinical outcomes using coronary CT angiography and FFRCT-guided management of stable chest pain patients. *J Am Coll Cardiol* 2018 Aug 21 [E-pub ahead of print].

- 13.** Kruk M, Wardziak L, Demkow M, et al. Workstation-based calculation of CTA-based FFR for intermediate stenosis. *J Am Coll Cardiol Img* 2016; 9:690-9.
- 14.** Ko BS, Cameron JD, Munnur RK, et al. Noninvasive CT-derived FFR based on structural and fluid analysis. *J Am Coll Cardiol Img* 2017;10:663-73.
- 15.** National Institute for Health and Care Excellence. Carfilzomib for previously treated multiple myeloma. 19 July 2017. Available at: <https://www.nice.org.uk/guidance/mtg32/chapter/1-Recommendations>. Accessed October 5, 2018.
- 16.** Sand NPR, Veien KT, Nielsen SS, et al. Prospective Comparison of FFR Derived From Coronary CT Angiography With SPECT Perfusion Imaging in Stable Coronary Artery Disease: the ReASSESS study. *J Am Coll Cardiol Img* 2018 Jun 9 [E-pub ahead of print].
- 17.** Cook CM, Petraco R, Shun-Shin MJ, et al. Diagnostic accuracy of computed tomography-derived fractional flow reserve: a systematic review. *JAMA Cardiol* 2017;2:803-10.
- 18.** Nakazato R, Park HB, Berman DS, et al. Noninvasive fractional flow reserve derived from computed tomography angiography for coronary lesions of intermediate stenosis severity: results from the DeFACTO study. *Circ Cardiovasc Imaging* 2013;6:881-9.
- 19.** Celeng C, Leiner T, Maurovich-Horvat P, et al. Anatomical and functional computed tomography for diagnosing hemodynamically significant coronary artery disease. *J Am Coll Cardiol Img* 2018 Sept 12 [E-pub ahead of print].
- 20.** Sørgaard MH, Linde JJ, Kühl JT, et al. Value of myocardial perfusion assessment with coronary computed tomography angiography in patients with recent acute-onset chest pain. *J Am Coll Cardiol Img* 2018;11:1611-21.
- 21.** Lubbers M, Coenen A, Kofflard M, et al. Comprehensive cardiac CT with myocardial perfusion imaging versus functional testing in suspected coronary artery disease. The multicenter, randomized CRESCENT-II trial. *J Am Coll Cardiol Img* 2018;11:10625-36.